During the past decade, Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 16 clinical trials were completed, i.e. on average, 145.5% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 8 clinical trials were completed. i.e. 160% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Celgene" with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Rigel Pharmaceuticals" with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika" #1 collaborator was "Pharmacyclics LLC." with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Fondazione Italiana Linfomi ONLUS" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "German Low Grade Lymphoma Study Group" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika" are "Follicular Lymphoma" (2 trials), "Multiple Myeloma" (2 trials), "Non-Hodgkin's Lymphoma" (2 trials), "Warm Antibody Autoimmune Hemolytic Anemia" (2 trials) and "Acute Lymphoblastic Leukemia" (1 trials). Many other conditions were trialed in "Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika" in a lesser frequency.

Most popular intervention types in "Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika" are "Drug" (23 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Obinutuzumab" (5 trials), "Placebo" (5 trials), "Rituximab" (5 trials), "Atezolizumab" (3 trials) and "Bendamustine" (3 trials). Other intervention names were less common.

The vast majority of trials in "Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika" are 23 trials for "All" genders.

Currently, there are NaN active trials in "Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 15 completed trials in Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika, 3 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".